Fortrea Q3'26 Earnings Conference Call - FORTREA HOLDINGS INC

Explicit Guidance:

• Full-year 2026 revenue guidance raised to $2.665 billion – $2.690 billion (previously narrowed ranges with raised midpoint).
• Full-year 2026 adjusted EBITDA guidance raised to $211 million – $218 million (previously narrowed ranges with raised midpoint).
• Q4 2026 guidance implies a sequential revenue slowdown due to fewer working days and higher leverage; Q4 adjusted EBITDA guidance implies a modest step-down in burn rate relative to Q3, with a Q4 burn rate assumption of approximately 8.5%.
• Full-year 2026 free cash flow expected to remain positive; Q4 2026 free cash flow expected to be positive.
• No explicit financial guidance provided for fiscal year 2027.

Business-Segment Outlook:

• Early Phase Services (CPS): Acquisition of Worldwide Clinical Trials' early phase services business completed (Oct 19, 2026); total U.S. and U.K. bed capacity now exceeds 570 (including 300-bed Texas network). Business targets EBITDA profitability by 2027.
• Revenue Mix: Anticipated transition from pass-through-heavy revenue to higher-economics direct fee (service fee) revenue. Low single-digit service fee revenue growth expected to begin generating incremental drop-through; mid-teens adjusted EBITDA margins targeted as growth accelerates to mid-single digits.
• Pipeline & Book-to-Bill: Trailing 12-month book-to-bill at 1.12x. Pipeline value increasing both sequentially and year-over-year. Biotech bookings saw almost double-digit growth in 2026; biopharma RFP inflow increasing significantly.
• Commercial Expansion: New leader appointed in China to drive growth with Chinese biotechs and multinationals. Targeting "new-to-Fortria" clients and winning share in biopharma refresh/RFP processes.
• Technology: "Fortria Intelligent Technology" (FIT) and CRA mobile app deployed in >49 countries to improve monitoring efficiency and site management; AI literacy program ("Felix") seeing >95% employee adoption.

Market and Competitive Outlook:

• Sector Recovery: Market environment characterized as being "square in the middle" of a recovery; biotech recovery led, followed by accelerating biopharma recovery.
• Competition: Belief that scale remains a critical differentiator; market view holds the top six CROs (including Fortria) as the viable players for large biopharma contracts.
• Pricing & Economics: Improved gross margins (backing out pass-throughs) driven by favorable portfolio mix and operational efficiencies, despite a ~200 bps headwind from increased workforce compensation investments.
• China Market: Continued positive tailwind; demand driven by multinationals investing in China trials and Chinese biotechs seeking global partnerships (US/EU). No negative impact observed from the COINS Act proposal.

Macro / Industry Outlook:

• Rates & FX: Higher benchmark interest rates impacted Q3 interest expense (variable rate debt ~40% of gross debt). Foreign currency headwinds estimated at 60 basis points for the nine months ended Sept 30, 2026.
• Regulatory/Geopolitical: Monitoring the COINS Act proposal; no current material disruption to China business operations or pipeline generation.
• Capital Allocation: Priorities include investing for organic growth, improving productivity, and steady deleveraging. Net leverage at 3.9x at quarter-end; acquisition impact on leverage estimated at ~0.25x (quarter turn).

Strategic Initiatives:

• M&A: Completed acquisition of Worldwide Clinical Trials' early phase services division; adding bioanalytical and safety lab capabilities to integrate with CRU networks. Transaction expected to be EBITDA profitable in 2027.
• Capacity Expansion: New 200-bed San Antonio facility and Austin bioanalytical lab creating a 300-bed Texas network; total global beds >570.
• Organic Investment: Continued investment in workforce compensation (approx. 200 bps margin headwind) to drive execution and retention; "Felix" AI literacy program and FIT technology rollout to enhance productivity.
• Geographic Strategy: Deepening presence in China through new leadership and leveraging "global from China" capabilities for cross-border trials.

Risks and Headwinds to Outlook:

• Backlog Adjustments: Recorded a $558 million cumulative adjustment to backlog to better reflect remaining life revenue, removing inactive trials and "not-to-deliver" dynamics; does not impact near-term revenue recognition but reduces future revenue visibility.
• Sequencing Variance: Q4 revenue slowdown expected solely due to fewer working days compared to Q3 and sequential productivity dynamics.
• Cost Pressures: Increased compensation investments acting as a margin headwind offsetting mix and efficiency gains.
• Execution Risk: Conversion of new capabilities (post-acquisition) and technology adoption (FIT/AI) into revenue and margin expansion may take time.
• Macro Sensitivity: Exposure to FX fluctuations and interest rate hikes on variable-rate debt (~40% of gross debt).

Management Tone on the Future:

• Confidence: High confidence in the "return to growth" strategy; leadership views the current trajectory as evidence of progress toward "mid-teens" adjusted EBITDA margins (the "true north").
• Strategic Shift: Emphasis on moving from cost optimization to "profitable growth" driven by operating leverage as service fee revenue scales.
• M&A Stance: Acquisition viewed as the "first step in a long journey" to establish Fortria as a "CRO of choice for evidence generation," with potential for further inorganic growth to fill capability gaps.
• Operational Focus: Shift from "task delivery" to "professional services organization" responsible for outcomes; strong emphasis on human-led execution combined with AI as a force multiplier.